• 011-26907444
  • raghava@iiitd.ac.in

Browse result page of AntiTbPdb

The total number entries retrieved from this search are 112
IDNameSequenceN-Terminal ModificationC-Terminal ModificationChemical ModificationLinear/CyclicLengthChiralityNatureSourceOriginSpeciesStrainInhibition ConcentrationIn vitro/ In vivoCell LineIntracellular InhibitionCytotoxicityAnimal ModelEffective Dose in model organismImmune ResponceMechanism of ActionTargetCombination TherapyOther ActivitiesYear of PublicationPubmed ID/ Patent No.
antitb_1132Human neutrophil defensin (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeInternal disulphide bond (cys2-cys30, cys4-cys19,cys9-cys29)Cyclic30LCationicProtein DerivedFrom the human defensin protein found in granules of neutrophils.Mycobacterium tuberculosis Mycobacterium tuberculosis H37Rv (ATCC 25618)50 mg/L causes approx 70 % growth inhibitionIn vitroNoneNANANone NANADisrupt the membrane architectureCell envelopeNoneAntibacterial against salmonella, staphylococcus and neisseria200111328767
antitb_1133Human neutrophil defensin (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeInternal disulphide bond (cys2-cys30, cys4-cys19,cys9-cys29)Cyclic30LCationicProtein DerivedFrom the human defensin protein found in granules of neutrophils.Mycobacterium tuberculosis Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain50 mg/L causes approx 30 % growth inhibitionIn vitroNoneNANANone NANADisrupt the membrane architectureCell envelopeNoneAntibacterial against salmonella, staphylococcus and neisseria200111328767
antitb_1136NK-2 KILRGVCKKIMRTFLRRISKDILTGKKFreeAmidationNoneLinear27LCationicProtein DerivedCore region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells Mycobacterium smegmatis Mycobacterium smegmatis mc2155 (ATCC 700084) 17.5 μg of NK-2/ml killed >90% M. smegmatis population after 24 h of incubation In vitroRAW264.7 No significant reduction in intracellular survival of M. smegmatis was observed No significant reduction in cell viability upto 100 μg/mlNone NANAPermeabilization of the bacterial cell membrane Cell envelopeNoneAntibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans)201323689720
antitb_1137NK-2 KILRGVCKKIMRTFLRRISKDILTGKKFreeAmidationNoneLinear27LCationicProtein DerivedCore region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells Mycobacterium smegmatis Mycobacterium smegmatis mc2155 (ATCC 700084) 7 μg of NK- 2/ml combined with 0.5 ppm of NP-1 kills 90% of M. smegmatisIn vitroRAW264.7 Combination of NP-1 and NK-2 showed 35% reduction in intracellular survival of M. smegmatis No significant reduction in cell viability either treating alone or combinationNone NANAPermeabilization of the bacterial cell membrane Cell envelopeAgNPs synthesiszed only in the presence of a plant Alstonia macrophylla (NP-1). Antibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans)201323689720
antitb_1138NK-2 KILRGVCKKIMRTFLRRISKDILTGKKFreeAmidationNoneLinear27LCationicProtein DerivedCore region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells Mycobacterium smegmatis Mycobacterium smegmatis mc2155 (ATCC 700084) 7 μg of NK- 2/ml combined with 0.5 ppm of NP-2 kills 90% of M. smegmatisIn vitroRAW264.7 NP-2 in combination with NK-2 killed >52% intra- cellular M. smegmatis.No significant reduction in cell viability either treating alone or combinationNone NANAPermeabilization of the bacterial cell membrane Cell envelopeAgNPs synthesiszed only in the presence of a fungal Trichoderma sp. (NP-2).Antibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans)201323689720
antitb_1139NK-2 KILRGVCKKIMRTFLRRISKDILTGKKFreeAmidationNoneLinear27LCationicProtein DerivedCore region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells Mycobacterium marinum Mycobacterium marinum (ATCC 927) IC90 = 3.5 μg/ml In vitroRAW264.7 Moderate killing was observedNo significant reduction in cell viability either treating alone or combinationNone NANAPermeabilization of the bacterial cell membrane Cell envelopeNoneAntibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans)201323689720
antitb_1140LLKKK-18 KEFKRIVKRIKKFLRKLFreeFreeNoneLinear17LAmphipathicProtein DerivedVariant of LL-37Mycobacterium smegmatis Mycobacterium smegmatis mc2155 (ATCC 700084) 25 μg of LLKKK-18/ml killed >80% of M. smegmatis after 24 h In vitroRAW264.7 No significant reduction in intracellular survival of M. smegmatis was observed No significant reduction in cell viability upto 25 μg/mlNone NANAPermeabilization of the bacterial cell membrane Cell envelopeNoneNone201323689720
antitb_1141LLKKK-18 KEFKRIVKRIKKFLRKLFreeFreeNoneLinear17LAmphipathicProtein DerivedVariant of LL-38Mycobacterium smegmatis Mycobacterium smegmatis mc2155 (ATCC 700084) 0.5 ppm of NP-1 combined with 1 μg/ml of LLKKK-18 kills 50% of M. smegmatisIn vitroRAW264.7 NP-1 in combination with LLKKK-18 kills 65% of mycobacteria compared to NP-1 or LLKKK-18 alone.No significant reduction in cell viability either treating alone or combinationNone NANAPermeabilization of the bacterial cell membrane Cell envelopeAgNPs synthesiszed only in the presence of a plant Alstonia macrophylla (NP-1). None201323689720
antitb_1142LLKKK-18 KEFKRIVKRIKKFLRKLFreeFreeNoneLinear17LAmphipathicProtein DerivedVariant of LL-39Mycobacterium smegmatis Mycobacterium smegmatis mc2155 (ATCC 700084) 0.5 ppm of NP-2 combined with 1 μg/ml of LLKKK-18 kills 89% of M. smegmatisIn vitroRAW264.7 No significant reductionNo significant reduction in cell viability either treating alone or combinationNone NANAPermeabilization of the bacterial cell membrane Cell envelopeAgNPs synthesiszed only in the presence of a fungal Trichoderma sp. (NP-2).None201323689720
antitb_1143LLKKK-18 KEFKRIVKRIKKFLRKLFreeFreeNoneLinear17LAmphipathicProtein DerivedVariant of LL-40Mycobacterium marinum Mycobacterium marinum (ATCC 927) IC 90 = 1 μg/ml In vitroRAW264.7 Moderate killing was observedNo significant reduction in cell viability either treating alone or combinationNone NANAPermeabilization of the bacterial cell membrane Cell envelopeNoneNone201323689720
antitb_1164hLFcin1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicProtein DerivedFrom human lactoferrin Mycobacterium aviumMycobacterium avium strain 2447 smooth transparent variant (SmT)IC50 = 15.8 ± 4.5In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1165hLFcin1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicProtein DerivedFrom human lactoferrin Mycobacterium aviumMycobacterium avium strain 2447 smooth transparent variant (SmT)IC90 =34.6 ± 22.4In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1166hLFcin1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicProtein DerivedFrom human lactoferrin Mycobacterium aviumMycobacterium avium strain 2-151 smooth transparent variant (SmT)IC50 = 11.0 ± 4.1In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1167hLFcin1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicProtein DerivedFrom human lactoferrin Mycobacterium aviumMycobacterium avium strain 2-151 smooth transparent variant (SmT)IC90 = 65.8 ± 19.3In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1168hLFcin1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicProtein DerivedFrom human lactoferrin Mycobacterium aviumMycobacterium avium strain 2-151 smooth doomed variant (SmD)IC50 = 15.2 ± 2.9In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1169hLFcin1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicProtein DerivedFrom human lactoferrin Mycobacterium aviumMycobacterium avium strain 2-151 smooth doomed variant (SmD)IC90 =37.9 ± 15.9In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1171LFcin17-30 FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicProtein DerivedFrom bovine lactoferricinMycobacterium aviumMycobacterium avium strain 2447 smooth transparent variant (SmT)IC50 = 14.2 ± 1.5In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1172LFcin17-30 FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicProtein DerivedFrom bovine lactoferricinMycobacterium aviumMycobacterium avium strain 2447 smooth transparent variant (SmT)IC90 = 18.9 ± 4.0In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1173LFcin17-30 FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicProtein DerivedFrom bovine lactoferricinMycobacterium aviumMycobacterium avium strain 2-151 smooth transparent variant (SmT)IC50 = 8.0 ± 1.5In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1174LFcin17-30 FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicProtein DerivedFrom bovine lactoferricinMycobacterium aviumMycobacterium avium strain 2-151 smooth transparent variant (SmT)IC90 = 22.8 ± 9.1In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1175LFcin17-30 FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicProtein DerivedFrom bovine lactoferricinMycobacterium aviumMycobacterium avium strain 2-151 smooth doomed variant (SmD)IC50 = 12.4 ± 0.3In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1176LFcin17-30 FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicProtein DerivedFrom bovine lactoferricinMycobacterium aviumMycobacterium avium strain 2-151 smooth doomed variant (SmD)IC90 = 21.5 ± 4.0In vitroNoneNANANone NANAPermeabilization of peptide causes significant changes both in the surface and in the ultrastructural organization of the mycobacterial cells.Cell envelopeNoneAntibacterial201424709266
antitb_1222PeptideSEFAYGSFVRTVSLPVConjugated with INHFreeConjugated with INH at N-terminalLinear16LNAProtein Derived91−106 region of the heat shock protein (Hsp16.3)NoneNoneNANANANANANA NANAInteract with Phospholipid Langmuir Monolayers and enhnaces the cell permating abiloity of INHPhospholipid Langmuir Monolayers Isoniazide (INH)None201323679078
antitb_1223Human neutrophil peptide 1 (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeDisulfide bridge: 2-30, 4-19, 9-29Cyclic30LNAProtein DerivedHuman neutrophilMycobacterium tuberculosis Mycobacterium tuberculosis H37Rv 96.5 % inhibition at 10 μg/mlIn vitroTHP-1 cells Significant reduction in CFUNANone NANANANANoneNone201323827033
antitb_1224Human neutrophil peptide 1 (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeDisulfide bridge: 2-30, 4-19, 9-30Cyclic30LNAProtein DerivedHuman neutrophilMycobacterium tuberculosis Mycobacterium tuberculosis H37Rv 98.3 % inhibition at 15 μg/mlIn vitroTHP-1 cells Significant reduction in CFUNANone NANANANANoneNone201323827033
antitb_1225Human neutrophil peptide 1 (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeDisulfide bridge: 2-30, 4-19, 9-31Cyclic30LNAProtein DerivedHuman neutrophilMycobacterium tuberculosis 36 Clinical isolates of Mycobacterium tuberculosis11 isolates (31%) showed greater sensitivity to HNP-1 than H37Rv strains. At 15 μg/ml, they wer completely inhibited.In vitroTHP-1 cells Sixteen clinical isolates had lower intracellular growth ability than the H37Rv strain. NANone NANANANANoneNone201323827033
antitb_1226Human neutrophil peptide 1 (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeDisulfide bridge: 2-30, 4-19, 9-32Cyclic30LNAProtein DerivedHuman neutrophilMycobacterium bovis Mycobacterium bovis BCG99.6 % inhibition at 10 μg/mlIn vitroTHP-1 cells Significant reduction in CFUNANone NANANANANoneNone201323827033
antitb_1227Human neutrophil peptide 1 (HNP-1)ACYCRIPACIAGERRYGTCIYQGRLWAFCCFreeFreeDisulfide bridge: 2-30, 4-19, 9-33Cyclic30LNAProtein DerivedHuman neutrophilMycobacterium bovis Mycobacterium bovis BCG100 % inhibition at 10 μg/mlIn vitroTHP-1 cells Significant reduction in CFUNANone NANANANANoneNone201323827033
antitb_1228High Activity Binding Peptides (HABPs) TGMAALEQYLGSGHAVIVSIFreeFreeNoneLinear20LNAProtein DerivedFrom Rv1268c protein Mycobacterium tuberculosis Mycobacterium tuberculosis H37Rv NAIn vitroalveolar epithelial cells A549 (ATCC No. CCL-185) Inhibited mycobacterial entry by up to 65%. NANone NANAInhibit mycobacterial entry into cellsNANoneNone201323993672
antitb_1229High Activity Binding Peptides (HABPs) AVALGLASPADAAAGTMYGDFreeFreeNoneLinear20LNAProtein DerivedFrom Rv1268c protein Mycobacterium tuberculosis Mycobacterium tuberculosis H37Rv NAIn vitroU937 monocyte derived macrophages (ATCC No. CRL-1593.2) Inhibited mycobacterial entry by up to 65%. NANone NANAInhibit mycobacterial entry into cellsNANoneNone201323993672
antitb_1260RN3 (1-45)RPPQFTRAQWFAIQHISLNPPRSTIAMRAINNYRWRSKNQNTFLRFreeFreeNoneLinear45LCationicProtein DerivedFrom the N terminus of RNase 3Mycobacterium vaccae Mycobacterium vaccae strain (ATCC 15483) MIC = 10.0 ± 0.5 μMIn vitroNoneNANANone NANAMembrane depolarization and permeabilizationCell envelopeNoneAntibacterial and Antiparasitic201323716047
antitb_1261RN3 (1-45)RPPQFTRAQWFAIQHISLNPPRSTIAMRAINNYRWRSKNQNTFLRFreeFreeNoneLinear45LCationicProtein DerivedFrom the N terminus of RNase 4Mycobacterium vaccae Mycobacterium vaccae strain (ATCC 15483) IC50 = 4.2 ± 0.2 μMIn vitroNoneNANANone NANAMembrane depolarization and permeabilizationCell envelopeNoneAntibacterial and Antiparasitic201323716047
antitb_1262RN7 (1-45)KPKGMTSSQWFKIQHMQPSPQASNSAMKNINKHTKRSKDLNTFLHFreeFreeNoneLinear45LCationicProtein DerivedFrom the N terminus of RNase 7Mycobacterium vaccae Mycobacterium vaccae strain (ATCC 15483) MIC = 20.0 ± 0.8 μMIn vitroNoneNANANone NANAMembrane depolarization and permeabilizationCell envelopeNoneAntibacterial and Antiparasitic201323716047
antitb_1263RN7 (1-45)KPKGMTSSQWFKIQHMQPSPQASNSAMKNINKHTKRSKDLNTFLHFreeFreeNoneLinear45LCationicProtein DerivedFrom the N terminus of RNase 8Mycobacterium vaccae Mycobacterium vaccae strain (ATCC 15483) IC50 = 9.5 ± 0.3 μMIn vitroNoneNANANone NANAMembrane depolarization and permeabilizationCell envelopeNoneAntibacterial and Antiparasitic201323716047
antitb_1264Cecropin A-melittin (CA-M) hybrid peptide KWKLFKKIGIGAVLKVLTTGLPALISFreeAmidationNoneLinear26LCationicProtein DerivedHybrid derived from cecropin A-melittinMycobacterium vaccae Mycobacterium vaccae strain (ATCC 15483) MIC = 20.0 ± 1.0 μMIn vitroNoneNANANone NANAMembrane depolarization and permeabilizationCell envelopeNoneAntibacterial and Antiparasitic201323716047
antitb_1265Cecropin A-melittin (CA-M) hybrid peptide KWKLFKKIGIGAVLKVLTTGLPALISFreeAmidationNoneLinear26LCationicProtein DerivedHybrid derived from cecropin A-melittinMycobacterium vaccae Mycobacterium vaccae strain (ATCC 15483) IC50 = 10.3 ± 0.3 μMIn vitroNoneNANANone NANAMembrane depolarization and permeabilizationCell envelopeNoneAntibacterial and Antiparasitic201323716047
antitb_1266F91SEFAYGSFVRTVSLPVGADEFreeFreeNoneLinear20LNAProtein DerivedFrom 16kDa antigenNoneNoneNAIn vivoNANANAFemale BALB/c mice (6-8 wk, 20±2 g) 20 nmolIt promotes the maturation of MHC-II and elicit secretion of IFN-Υ and also induce the expression of CD80, CD86 and CD40 co-stimulatory molecules and activate DCs to produce IL-6 and IL-12.NANANoneNA201324434326
antitb_1267L91SEFAYGSFVRTVSLPVGADEFreeFreeConjugated to TLR2-ligand Pam2CysLinear20LNAProtein DerivedFrom 16kDa antigenNoneNoneNAIn vivoNANANAFemale BALB/c mice (6-8 wk, 20±2 g) 20 nmolIt promotes the maturation of MHC-II and elicit secretion of IFN-Υ and also induce the expression of CD80, CD86 and CD40 co-stimulatory molecules and activate DCs to produce IL-6 and IL-12.NANANoneNA201324434326
antitb_1268VapB30 (52-59)ELAAIRHRFreeFreeNoneLinear8LNAProtein DerivedFrom VapB30 toxinMycobacterium tuberculosis Mycobacterium tuberculosis (strain H37Rv) NANANANANANone NANABy disrupting the toxin-antitoxin complex (VapBC)VapBCNoneNA201526150422
antitb_1269VapC30 (14-30)DEPDAERFEAAVEADHIFreeFreeNoneLinear17LNAProtein DerivedFrom VapC30 toxinMycobacterium tuberculosis Mycobacterium tuberculosis (strain H37Rv) NANANANANANone NANABy disrupting the toxin-antitoxin complex (VapBC)VapBCNoneNA201526150422
antitb_1270VapC30 (48-56)RFGEPGGREFreeFreeNoneLinear9LNAProtein DerivedFrom VapC30 toxinMycobacterium tuberculosis Mycobacterium tuberculosis (strain H37Rv) NANANANANANone NANABy disrupting the toxin-antitoxin complex (VapBC)VapBCNoneNA201526150422
antitb_1330Human beta casein fragment (54-59)VEPIPYFreeFreeNoneLinear6LCationicProtein derivedHuman beta casein proteinMycobacterium bovis Mycobacterium bovis BCGMIC = 25μMin vitroTHP 1 cell linesCells treated with 10 mM and 20 mM peptide showed 17.13% and 29.56% increase in clearance of BCG NANA NAIncrease expression of IL-8, MCP-1, MIP-1β, TNF-αNANANANA201223029305
antitb_1439A2-TB10.4 IMYNYPAML FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1440A2-TB10.4 AMLGHAGDM FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1441A2-TB10.4 MLGHAGDMA FreeFreeNoneLinear9LNAProtein derivedMTB derived protein TB10.4Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1442A2-Ag85B YLLDGLRAQ FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1443A2-Ag85B KLVANNTRL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1444A2-Ag85B FIYAGSLSA FreeFreeNoneLinear9LNAProtein derivedMTB derived protein Ag85B Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1445A2-ESAT6 AMASTEGNV FreeFreeNoneLinear9LNAProtein derivedMTB derived protein ESAT6 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751
antitb_1446A2-ESAT LLDEGKQSL FreeFreeNoneLinear9LNAProtein derivedMTB derived protein ESAT6 Mycobacterium tuberculosisMycobacterium tuberculosis RvNANANANANANA NAIL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatmentDrug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. CD8+ T-cellNANA210425809751